The FDA Oncologic Drugs Advisory Committee agreed with the agency’s forcefully stated view that Lynparza (olaparib), a PARP inhibitor, should be given only to metastatic castration-resistant prostate cancer patients whose tumors have a BRCA mutation.
Does anyone have more insight into this finding?
Written by
JRPnSD
To view profiles and participate in discussions please or .
I think this may be misguided. While I was at Johns Hopkins, my MO there tried to recruit me into a trial using Olaparib claiming that it would set the disease back years perhaps with long-term remission. the only catch to me entering this trial was that my T had to be a lot higher than it was so I was rejected. I assumed that he knew what he was talking about so I think that waiting too late into a patient's disease progression may be merely adding months to a lifespan vs. the potential for years. I am double BRCA2--germline and somatic.
This g+sBRCA2m+ , g+sATMm+, sFOXA1m+ guy agrees with your sense. PARPi's (as olaparib) are being used as maintenance therapies with other cancers and broadly under trials for many applications, even cancer preventatives for HRDm+ people/previvors. FDA may simply be reacting to the intense interest in (and marketing?) of PARPi's. MD's, especially MOs are still able to prescribe drugs off label (blessedly...) Stay tuned, especially in 5-10 years out.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.